Carl Mauch - Tcr2 Therapeutics Sr Communications
Insider
Carl Mauch is Sr Communications of Tcr2 Therapeutics
| Phone | 617 949 5200 |
| Web | https://www.tcr2.com |
Tcr2 Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.3473) % which means that it has lost $0.3473 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9146) %, meaning that it created substantial loss on money invested by shareholders. Tcr2 Therapeutics' management efficiency ratios could be used to measure how well Tcr2 Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Tcr2 Therapeutics currently holds 58.23 M in liabilities with Debt to Equity (D/E) ratio of 0.29, which may suggest the company is not taking enough advantage from borrowing. Tcr2 Therapeutics has a current ratio of 4.92, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Tcr2 Therapeutics' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Kimberly Pope | ADC Therapeutics SA | 58 | |
| Dawn Kalmar | Stoke Therapeutics | 47 | |
| Craig Winter | Agenus Inc | N/A | |
| Jack Anders | Revolution Medicines | 49 | |
| Angus Smith | Affimed NV | 42 | |
| Christopher Roberts | Black Diamond Therapeutics | 54 | |
| Pr Little | Affimed NV | N/A | |
| Walter Reiher | Revolution Medicines | N/A | |
| Regina Grebla | Agenus Inc | N/A | |
| TaiAn Lin | Black Diamond Therapeutics | N/A | |
| Peter Greaney | ADC Therapeutics SA | 41 | |
| Julie DeSander | Agenus Inc | N/A | |
| Elizabeth Buck | Black Diamond Therapeutics | 50 | |
| David Epstein | Black Diamond Therapeutics | 66 | |
| Marc MD | Alector | 51 | |
| Richard Onyett | ADC Therapeutics SA | 73 | |
| Path FRCP | Revolution Medicines | 61 | |
| Kevan Shokat | Revolution Medicines | N/A | |
| Robert Schmidt | ADC Therapeutics SA | 43 | |
| Uwe Reusch | Affimed NV | N/A | |
| David Pompliano | Revolution Medicines | N/A | |
Management Performance
| Return On Equity | -0.91 | |||
| Return On Asset | -0.35 |
Tcr2 Therapeutics Leadership Team
Elected by the shareholders, the Tcr2 Therapeutics' board of directors comprises two types of representatives: Tcr2 Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Tcr2. The board's role is to monitor Tcr2 Therapeutics' management team and ensure that shareholders' interests are well served. Tcr2 Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Tcr2 Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Angela Justice, Chief Officer | ||
| Patrick Baeuerle, Founder Board | ||
| Richard Roomberg, VP Controller | ||
| Dr MBA, CEO Pres | ||
| Margaret JD, Head Sec | ||
| Rosemary Harrison, Chief Officer | ||
| Peter Olagunju, Chief Officer | ||
| Alfonso MD, Chief Officer | ||
| Carl Mauch, Sr Communications | ||
| Eric CPA, Chief Officer |
Tcr2 Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Tcr2 Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.91 | |||
| Return On Asset | -0.35 | |||
| Current Valuation | (73.69 M) | |||
| Shares Outstanding | 39.26 M | |||
| Shares Owned By Insiders | 1.50 % | |||
| Shares Owned By Institutions | 54.31 % | |||
| Number Of Shares Shorted | 360.89 K | |||
| Price To Book | 0.22 X | |||
| EBITDA | (89.62 M) | |||
| Net Income | (151.82 M) |
Pair Trading with Tcr2 Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Tcr2 Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Tcr2 Therapeutics will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Microsoft could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Microsoft when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Microsoft - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Microsoft to buy it.
The correlation of Microsoft is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Microsoft moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Microsoft moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Microsoft can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Other Consideration for investing in Tcr2 Stock
If you are still planning to invest in Tcr2 Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Tcr2 Therapeutics' history and understand the potential risks before investing.
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |